71 results
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
1 Aug 19
Entry into a Material Definitive Agreement
12:35pm
Arcturus Therapeutics Receives up to $15 Million Commitment from the Cystic Fibrosis Foundation to Create mRNA Therapies to Treat Cystic Fibrosis … that the Cystic Fibrosis Foundation (CF Foundation), has increased its commitment to $15 million in conjunction with an amended agreement to advance LUNAR-CF
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
15 Aug 19
Arcturus Therapeutics Announces Second Quarter Financial Results and Provides a Corporate Update
8:09am
. expands collaboration, becoming Arcturus’ largest shareholder
Cystic Fibrosis Foundation increases commitment to $15 million
Arcturus receives Orphan … commitment up to $15 million to fundLUNAR-CF program through IND filing, with the first payment of $4 million expected by the end of August 2019
Received
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
18 Aug 20
Arcturus Therapeutics Executes Definitive Supply Agreement with the Israeli Ministry of Health
4:01pm
Ministry of Health’s commitment to our differentiating STARR™ mRNA vaccine candidate and we look forward to advancing the development of ARCT-021 … applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment to the development of novel RNA therapeutics has led
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
26 Sep 23
Entry into a Material Definitive Agreement
4:06pm
to Treat Cystic Fibrosis
CF Foundation Increases Financial Commitment to ~$25 Million
SAN DIEGO--(BUSINESS WIRE)--Sept. 26, 2023-- Arcturus Therapeutics … Foundation (CF Foundation) have extended their ongoing agreement. The CF Foundation agreed to increase its financial commitment to ~$25 million to advance ARCT
8-K
EX-99.1
ARCT
Arcturus Therapeutics Holdings Inc
20 Jun 19
License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases
6:06am
.”
“The expansion of the collaboration with Ultragenyx underscores the partnership’s early successes and ongoing commitment,” said Joseph Payne, President and Chief … patent portfolio (154 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus’ commitment
8-K12B
EX-99.1
5ooun1o
14 Jun 19
Notification of registration of securities
5:10pm
8-K
EX-99.1
73o0261n7yosbcfohmf
14 Nov 23
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update
4:10pm
8-K
EX-1.1
0u2d9aa4geipz3
2 Aug 19
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
4:29pm
8-K
EX-1.1
breldge0xgvp94
27 Sep 19
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
4:25pm
8-K
EX-99.1
a7acbt1 vb
22 Feb 21
Arcturus Therapeutics Acquires Exclusive License to mRNA Manufacturing Technology from Alexion Pharmaceuticals
5:00pm
8-K
qf37h4z1v58
21 Apr 23
Entry into a Material Definitive Agreement
5:21pm
8-K
EX-99.1
aw48nr53q 3t
13 Dec 21
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
5:17pm
8-K
EX-99.1
prcs0iivst2a3cf mkc
5 Aug 19
Arcturus Therapeutics Announces $2.3 Million Additional Registered Direct Offering of Common Stock
9:14am
8-K
EX-99.1
f1ett5 q5kxpz
2 Aug 19
Arcturus Therapeutics Announces $10.9 Million Registered Direct Offering of Common Stock
4:29pm
8-K
EX-99.1
z2f0iptvc0
27 Sep 19
Arcturus Therapeutics Announces $9.8 Million Registered Direct Offering of Common Stock
4:25pm
8-K
EX-99.1
v86 2ipbkb4t42kczw
1 Sep 22
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of
5:09pm
8-K
EX-99.1
50x6 9y5zoy9
24 Jul 20
Israel secures rights to stockpile and reserve doses of LUNAR-COV19 for its citizens
6:02am
8-K
EX-99.1
h75knr
23 Sep 19
Arcturus Therapeutics Announces Appointment of Dr. Edward Holmes M.D. andRe-Appointment of Andy Sassine to the Board of Directors
4:34pm